EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer

Chao He, Zheng Zhou, Yan Yang, Songting Zhu, Haiyong Wang, Lisong Teng iD

Gastric Cancer · 2025

DOI: 10.1007/s10120-025-01602-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gastric Cancer, 2025. Verfasst von Chao He und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Peritoneal Neoplasms, Anoikis, Extracellular Matrix. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Zhejiang Province, National Science and Technology Planning Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peritoneal metastasis is a critical step in the progression of gastric cancer (GC), yet its underlying mechanisms remain poorly understood. Here, we identify FERMT2, a member of the Kindlin protein family, as a key regulator of anoikis resistance (AR) and peritoneal metastasis in GC. FERMT2 expression increases in a suspension-time-dependent manner and is associated with higher pathological grade, advanced clinical stage, and poorer prognosis. Functional studies in vitro and in vivo demonstrate that FERMT2 promotes AR and facilitates peritoneal metastasis. Mechanistically, FERMT2 suppresses the ubiquitination of SOX2, thereby enhancing its stability and up-regulating FN1 transcription. Furthermore, we report that TGFβ-RI expression also increases in a suspension-time-dependent manner, forming a positive feedback loop with FERMT2 via TGFβ-1/TGFβ-RI signaling. This feedback loop drives extracellular fibronectin matrix deposition, strengthens cell–matrix interactions, and supports AR. These findings establish FERMT2 as a pivotal mediator of peritoneal metastasis in GC, offering insights into its potential as a therapeutic target.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsPeritoneal NeoplasmsAnoikisExtracellular MatrixMembrane ProteinsNeoplasm ProteinsHumansAnimalsMicePrognosisFemaleMaleFibronectinsMice, NudeGene Expression Regulation, NeoplasticSignal TransductionCell Line, Tumor

Stichwörter der Autor:innen

Anoikis resistanceFERMT2Gastric cancerMetastasis

Substanzen

Membrane ProteinsNeoplasm ProteinsFibronectins

Autor:innen und Institutionen

  • Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. lsteng@zju.edu.cn.

ORCID-Profile: Lisong Teng

Förderung

  • Key Research and Development Program of Zhejiang Province
  • National Science and Technology Planning Project

Zitieren

APA

He, C., Zhou, Z., Yang, Y., Zhu, S., Wang, H., & Teng, L. (2025). FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer. Gastric Cancer. https://doi.org/10.1007/s10120-025-01602-0

Vancouver

He C, Zhou Z, Yang Y, Zhu S, Wang H, Teng L. FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer. Gastric Cancer. 2025. doi:10.1007/s10120-025-01602-0

BibTeX
@article{He2025,
  author = {He, Chao and Zhou, Zheng and Yang, Yan and Zhu, Songting and Wang, Haiyong and Teng, Lisong},
  title = {FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer},
  journal = {Gastric Cancer},
  year = {2025},
  doi = {10.1007/s10120-025-01602-0}
}
Kostenlos starten →